{"entity":{"id":"nct05662397","kind":"trial","name":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody","aka":[],"tldr":"A phase 1/2 trial of Cemiplimab in advanced solid tumours, run by HotSpot Therapeutics, Inc, active and no longer recruiting.","summary":"A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody is a phase 1/2 interventional study registered as NCT05662397 by HotSpot Therapeutics, Inc, with 77 participants enrolled, started 2023-03-15 and due to reach its primary completion in 2025-12-31. Interventions recorded: HST-1011 and Cemiplimab.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05662397","url":"https://clinicaltrials.gov/study/NCT05662397"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["cemiplimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05662397","phase":"1/2","setting":"An Open Label, Phase 1/2 Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors","sponsor":"HotSpot Therapeutics, Inc","enrolled":77,"outcomes":[]},"route":"/trials/nct05662397/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"},{"id":"hst-1011","kind":"drug","name":"HST-1011","route":"/drugs/hst-1011/"}]}}